Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081887 | 0.83 | CYP19A1 (0.64) | CYP19A1LMNAHDAC1HDAC6 | |
| SCHEMBL2562677 | 0.83 | CYP19A1 (0.60) | CYP19A1HDAC1HDAC6STS | |
| SCHEMBL7079785 | 0.81 | CYP19A1 (0.56) | CYP19A1LMNAHDAC1HDAC6 | |
| SCHEMBL950133 | 0.78 | CYP19A1 (0.62) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL2917482 | 0.77 | CYP19A1 (1.00) | CYP19A1LMNAHDAC1HDAC6 | |
| SCHEMBL7073644 | 0.77 | HDAC1 (0.53) | CYP19A1LMNAHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL9382670 | 0.76 | CYP19A1 (0.96) | CYP19A1LMNAHDAC1HDAC6 | |
| SCHEMBL6479536 | 0.74 | CYP19A1 (0.48) | CYP19A1LMNAHDAC1HDAC6STS | |
| SCHEMBL14496521 | 0.72 | CYP19A1 (0.57) | CYP19A1LMNAHDAC1HDAC6STS | |
| SCHEMBL9023539 | 0.71 | CYP19A1 (0.86) | CYP19A1LMNAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | ZHUANG LINGHANG (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1333831-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036734-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | POLI, CYP51A1, DUT | CYP19A1 91/4885LMNA 1130/4885HDAC1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.